ARTA
ADMA icon

A.R.T. Advisors’s ADMA Biologics ADMA Stock Holding History

A.R.T. Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-35,029
Closed -$140K – 50
2019
Q4 		$140K Buy
+35,029
New +$153K 0.01% 1196
2019
Q3 		– Sell
-70,665
Closed -$273K – 1398
2019
Q2 		$273K Buy
70,665
+51,700
+273% +$228K 0.02% 993
2019
Q1 		$72K Buy
+18,965
New +$67K ﹤0.01% 1199

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

A.R.T. Advisors's ADMA Position: Q1 2020 in Review

A.R.T. Advisors sold out of ADMA Biologics (ADMA) in Q1 2020, closing a stake of 35,029 shares — an estimated $140K sold.

A.R.T. Advisors first reported a position in ADMA in Q1 2019 and held it in 3 quarters. The position peaked at $273K in Q2 2019. 91 funds tracked by Wall St. Rank hold ADMA as of Q1 2020.

  • A.R.T. Advisors reported no remaining ADMA Biologics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 35,029 ADMA Biologics shares in Q1 2020, an estimated $140K.
  • A.R.T. Advisors first reported a position in ADMA Biologics in Q1 2019 and held it in 3 quarters.
  • A.R.T. Advisors's ADMA Biologics position peaked at $273K in Q2 2019.
  • 91 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.